Axsome Therapeutics is trading 4.19% down at $196.87 in pre-market, with no clear company-specific catalyst identified for the September 22, 2026, decline.
- Recent coverage focused on Psych Congress clinical data and caregiver-survey results.
- Broader U.S. futures were only modestly lower.
- The move follows several weaker sessions, including a 5.78% decline on September 15, but its immediate cause remains unclear.